Ver­tex CMO Jef­frey Chodake­witz is hit­ting the ex­it doors. What's next?

Just days af­ter the launch of Ver­tex’s big Phase III study of its lead cys­tic fi­bro­sis triple ther­a­py, the big biotech is bid­ding farewell to its high pro­file chief med­ical of­fi­cer, Jef­frey Chodake­witz.

The CMO has been with Ver­tex for four years, jump­ing ship from phar­ma gi­ant Mer­ck, where he held a top R&D po­si­tion.

There’s no im­me­di­ate word about what Chodake­witz has in mind for the next chap­ter, on­ly the usu­al in­dus­try an­nounce­ment that he is re­tir­ing. Typ­i­cal­ly all se­nior ex­ecs in bio­phar­ma “re­tire,” whether they were pushed or jumped, plan to keep work­ing or not.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER